371 related articles for article (PubMed ID: 19199980)
21. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
22. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Brown WV
Am J Cardiol; 2008 Dec; 102(12A):10L-13L. PubMed ID: 19084084
[TBL] [Abstract][Full Text] [Related]
23. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.
Toth PP; Simko RJ; Palli SR; Koselleck D; Quimbo RA; Cziraky MJ
Cardiovasc Diabetol; 2012 Sep; 11():109. PubMed ID: 22978715
[TBL] [Abstract][Full Text] [Related]
24. Lipids, lipid-lowering therapy and diabetes complications.
Valensi P; Picard S
Diabetes Metab; 2011 Feb; 37(1):15-24. PubMed ID: 21126902
[TBL] [Abstract][Full Text] [Related]
25. Preventing diabetic complications: a primary care perspective.
Zimmet P
Diabetes Res Clin Pract; 2009 May; 84(2):107-16. PubMed ID: 19278746
[TBL] [Abstract][Full Text] [Related]
26. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
[TBL] [Abstract][Full Text] [Related]
27. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Wierzbicki AS
Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
[TBL] [Abstract][Full Text] [Related]
28. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
29. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Després JP
Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
[TBL] [Abstract][Full Text] [Related]
30. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Wong TY; Simó R; Mitchell P
Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
[TBL] [Abstract][Full Text] [Related]
31. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
Varghese Z; Moorhead JF; Ruan XZ
Kidney Int; 2006 May; 69(9):1490-1. PubMed ID: 16672917
[TBL] [Abstract][Full Text] [Related]
32. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
33. Diabetic dyslipidaemia: insights for optimizing patient management.
Vergès B
Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
[TBL] [Abstract][Full Text] [Related]
34. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
35. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
36. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
37. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
38. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
39. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
[TBL] [Abstract][Full Text] [Related]
40. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
